

Global Parkinson's Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson's disease

Supplementary Information

Contents

GP2 Consent Guidelines and Recommended Language	1
2. Clinical Cohort Meta-Data	5
3. GitHub Links	5
4. Cohort Site Interest Form	5
5. Map of contributing cohorts and genotyping tracker	21
6. Contributing Institutions	21
7. Sample preparation and shipment guidelines for genotyping at NIH, Maryland, USA	22
8. Sample preparation and shipment guidelines for genotyping at Fulgent, Californ USA.	nia, 24
9. Sample preparation and shipment guidelines for genotyping at DZNE, Tübinger Germany.	Դ, 26

1. GP2 Consent Guidelines and Recommended Language

The GP2 Consent Guidelines and Recommended Language can be viewed and downloaded at https://gp2.org/resources/consent-guidelines/. The current guidelines (Version October 2020) are below.



Consent Guidelines & Recommended Language Summary

The Global Parkinson's Genetics Program (GP2) has developed the following template text to assist researchers who wish to submit samples and/or data to GP2. The template text is intended as a guide, and it can be adapted to reflect local requirements. However, the content should remain true to the goal of international data sharing. When developing your consent document, please be sure to include any additional content required by your local ethics review board which may not be listed below.

Introduction

If not consenting as part of another study: You are invited to take part in the Global Parkinson's Genetics Program (GP2). This is a research project. Researchers from around the world are collaborating through this project to study the genetics of Parkinson's Disease. GP2 includes people with and without Parkinson's Disease. You can find information about GP2 and the researchers leading the program at www.gp2.org.

At [name of institution], this project is being led by [name of investigator]. All research that uses peoples' personal data must be reviewed by an ethics board or committee. This project has been approved by [ethics board/committee information]. GP2 is funded by the Aligning Science Across Parkinson's (ASAP) initiative and The Michael J. Fox Foundation for Parkinson's Research.

<u>If consenting as part of another study:</u> You are invited to take part in [name of study]. This is a research project. [Explain the purpose of this study. Provide details regarding the institution(s), investigator(s), and ethics board review.]

[Name of study] is collaborating with researchers from around the world through the Global Parkinson's Genetics Program (GP2) to study the genetics of Parkinson's Disease. GP2 includes people with and without Parkinson's Disease. You can find more information about GP2 and the researchers leading the program at www.gp2.org.

Voluntariness

Your participation in this study is voluntary. The decision about whether or not to participate is completely up to you. If you choose not to participate in the study, your choice will not affect your medical care.

Research activities

<u>If not consenting as part of another study</u>: If you choose to participate, you will be asked to provide a small sample (less than a tablespoon) of blood [or saliva]. You will also be asked questions about your health and your family history of Parkinson's Disease.

<u>If consenting as part of another study</u>: [Explain the activities involved in this study. Include the collection of a blood or saliva sample for DNA.]

Payment for Participation

[GP2 will not provide payment for participation. If subjects will be reimbursed for time/inconvenience related to your research activities, please specify.]

[For US studies, specify cost/no-cost to participate.]

For more information check the Global Parkinson's Genetics Program (GP2) website www.gp2.org or email info@gp2.org



Define the research data - genomic and personal data

Your sample will be used to generate genomic data. Genes are the basic 'instruction book' for the cells that make up our bodies. Genes are made out of DNA, and all of the DNA in each cell is called the genome. Although our DNA is very similar to each other, your genomic data is entirely unique.

Other types of data about you will also be collected. This may include information about your sex, age, ethnicity, and diseases or syndromes you may have.

Data coding (or pseudonymization)

Information that directly identifies you, such as your name, will be replaced with a 'code' or 'ID number.' Your name and other identifying information will not be shared with other researchers.

Describe future use

Your samples and data will be used to learn about the genetic differences between people with and without disease. They may also be used in additional research studies involving PD, other neurological conditions, other types of disorders, or other biomedical research studies. These additional studies may involve development of cures, therapies and products and services for the benefit of PD and other patients.

Explain international sharing

This research may be conducted anywhere in the world; the researchers studying your samples and data may be located outside your country. These projects can also take place in universities, hospitals, nonprofit groups, for-profit companies, or government laboratories.

Include commercial/non-academic use

Your sample and data are a gift for research. The future research projects may take place in universities, hospitals, nonprofit groups, for-profit companies, or government laboratories.

Some of the research done with your information may one day lead to new software, tests, drugs, or other commercial products. If this happens, you will not receive any of the profits from these new products.

Explain managed access (and unrestricted access for aggregate data)

Your coded data, will be stored on a secured data platform. Information in this data platform can only be accessed and used by researchers who have been granted formal approval to access data and who have signed agreements to protect the confidentiality of the information. The access agreements also require researchers to respect the laws and ethical guidelines for scientific research.

Your coded data may also be combined with data from many thousands of other people in large-scale analyses. A summary of this data may be made public (openly accessible) to anyone without restriction.

Include storage on cloud servers

Your coded data will be stored on one or more data platforms coordinated by multiple institutions that can be used by researchers around the world. These researchers may be conducting their own projects or may be working on projects coordinated by the sponsors.

For more information check the Global Parkinson's Genetics Program (GP2) website www.gp2.org or email info@gp2.org



The data platform may be hosted on commercial cloud servers. The cloud refers to software and services that run on the Internet, instead of on a specific computer. These cloud servers meet international security and safety standards.

Do not limit duration of storage

<u>Preferred:</u> Your coded samples and/or data will be stored indefinitely or until they are withdrawn or no longer useful for current or future research.

If indefinite storage is not allowed: Your coded samples and/or data may be stored and used for research for 30 (thirty) years.

Explain data withdrawal

You may withdraw consent for research use of your samples and data at any time. If you choose to withdraw, your samples will be destroyed, and your data will be removed from the data platform. However, it may not be possible to retrieve data that has already been distributed for research use.

Request consent to contact the participant for future research

With your permission, we may re-contact you to invite you to provide additional data or to be involved in new research projects.

[Please verify requirements for consent to recontact with your ethics board].

Discuss lack of benefit and risk of re-identification

You will not benefit personally from sharing your data. Participating in the study may help researchers in many areas of scientific research, such as health and genetics.

Your information will be coded, which means it will not be connected to any information that directly identifies you, such as your name, address, and contact information. However, it is very difficult to make genetic information completely anonymous. There is a risk that people that have your information could try to connect it to your identity by combining it with other personal information about you, through a process called re-identification. Also, in the future, new technologies could be developed that make it easier to connect your genetic information to your identity. The risks related to re-identification are difficult to predict at this time.

Because genetic information is shared among people who are biologically related to you, it is possible that information about your family members could also be revealed.

There is always a risk that information from genetic studies might be used to make certain statements or conclusions about groups or communities. In some cases, this can lead to discrimination against individuals, families, groups or communities.

Contacts

[Provide contact information for both local study staff and the regulatory/ethics authority.]

For more information check the Global Parkinson's Genetics Program (GP2) website www.gp2.org or email info@qp2.org



2. Clinical Cohort Meta-Data

GP2 is collecting information regarding other biosample and data types that are available for contributing cohorts. These samples/data will not be requested or shared by GP2. The information is intended to allow investigators to identify collaborators with similar interests and available data for auxiliary studies e.g., biomarker or imaging studies. The below table gives an indication of the availability of these data/sample types as of May 15th 2022.

Data/sample modality	Number of cohorts with available data/samples
MRI	43
DAT Scan	34
Plasma	57
Serum	55
RNA	28
PBL	21
LCL	3
CSF	24
Skin Biopsy	22
iPS	15
Post-mortem Brain Tissue	15

3. GitHub Links

Global Parkinson's Genetics Program – Code (Main GP2 repository): https://github.com/GP2code

Neuro Booster Array:

https://github.com/GP2code/Neuro Booster Array

4. Cohort Site Interest Form

Below is a blank copy of the Site Interest Form that cohort Investigators are asked to complete to register their interest in joining GP2. The submitted form is reviewed by the Cohort Integration Working Group to determine whether the cohort should be included. The numbers entered into the form can be approximate; it is intended to provide an overview of the cohort and samples/data availability. Investigators who are interested in joining GP2 can complete the live form here: https://forms.gle/tAEfZHu94jpu8g6i9



GP2 complex trait group: Site Interest Form (Version 2)

Thank you for your interest in collaboration. We would like to ask some general questions about your cohort, number of available (will be available) data and samples, genotyping chips, and IRB approved information especially for data sharing policies. The form consists of 8 sections and will take 20 minutes to fill in. You can edit the input after you submit it. If you have any questions please contact gp2cohort@parkinsonsroadmap.org.

*R	*Required		
1.	Email *		
2.	NAME *		
3.	INSTITUTION *		
4.	SHORT NAME OF STUDY *		
5.	FULL NAME OF STUDY *		
6.	PI *		
7.	email *		



8.	Year Started *	
9.	Year Completed *	
10.	FOLLOW UP COMPLETED * 4-digit, 9999 if the end is not planned	
11.	Is this a multi-site study? * Mark only one oval. Yes No	
12.	What is the main setting of the study (ma	n location of recruitment)? *
13.	Who are the participants? * Tick all that apply. PD only PD cases and controls Defined PD group, e.g. early onset PD, fami Other:	lial PD, DBS



14.	What is the study context? *
	Mark only one oval.
	Observational study
	Interventional study e.g. drug trial
15.	What is the study timespan? *
	Mark only one oval.
	Cross-sectional: one assessment only, with no further contact
	Cross-sectional plus: one assessment with further questionnaires, EPR, Mortality follow-up
	Longitudinal (prospective): multiple face-to-face assessments
	Longitudinal (retrospective)
16.	Planned follow-up duration and visit intervals e.g. 5 years and every 6 month. (Skip this question if not longitudinal)
17.	Main Study Site Region *
	Mark only one oval.
	North America
	South America
	Europe
	Africa
	Asia/Oceania
	No main region but multi-region
18.	Country of main site *



19.	Publication DOI or webpage describing study design
St	udy Participants
20.	Rough breakdown of ancestry - Europeans (%) * Among those with blood/DNA samples
21.	Rough breakdown of ancestry - Africans (%) * Among those with blood/DNA samples
22.	Rough breakdown of ancestry - Asians (%) * Among those with blood/DNA samples
23.	Inclusion criteria: what criteria was used to confirm/diagnose PD cases? Mark only one oval. MDS Diagnostic criteria UK Brain Bank criteria Other:
24.	Inclusion criteria: what are the disease stage criteria for recruiting PD cases? E.g. diagnosis < 5 years, symptom onset < 3 years, Hoehn and Yahr stage < 3, no medication etc.



	, no family history etc.
What are th	ne inclusion criteria for controls?
Are there a	ny other specific recruitment features?
Are there a	ny other specific recruitment features?
Are there a	ny other specific recruitment features?
Are there a	ny other specific recruitment features?
	ny other specific recruitment features? percentage (%) with post-mortem confirmation of diagnosis? *
What is the	



29.	Name and version of ge "NA" if genotyping has not bee	
30.	Number of SNPs on the Rough number is fine (e.g. 230	chip * K, 510K, 1M). "NA" if genotype has not been done/planned.
	urrently available data d samples	For the following questions, please answer based on the current availability of data/samples.
31.	Number of participants Those with the clinical data ava	
32.	·	whose DNA is currently available * specimen, please DO NOT include them here.
33.	•	whose genotype is currently available * nd can be transferred to NIA. 0 otherwise
34.	Number of participants Those with the clinical data ava	
35.	•	cicipants whose DNA is currently available * specimen, please DO NOT include them here but include then in the



36.	Number of non	-PD participants whose genotype is currently available *
37.	Shipping currer	nt DNA samples *
	and samples will be check the box below	o be genotyped at NIH with a custom array for neurodegenerative disorders. Data returned to submitting sites. If it is impossible to send DNA samples to NIH, please v. This will be subject to MTA and collaborative agreements but an initial indication your study will be helpful
	Mark only one o	val.
	We anticipa	ate we will be able to send samples to NIH for genotyping
	We anticipa	ate we will not be able to send samples to NIH for genotyping
	We do not	know the situation with transferring samples at this time
	NIH(NIA) s	hould have had all the DNA samples already
	Other:	
dat exp ava	ditional ta/sample pected to be ailable by the d of 2022	NIA needs to receive samples by the end of 2022 at the latest. For the ongoing study, please provide your best guess about the additional availability of data and samples by the end of 2022. For the completed study, please provide 0 for all questions in this section.
38.	Number of ADI	DITIONAL PD patients *
39.	2022	DITIONAL PD patients whose DNA will be available by the end of * ants with blood/specimen but DNA have not been extracted yet
40.	Number of ADD end of 2022	DITIONAL PD patients whose genotype will be available by the *



41.	Number of ADDITIONAL non-PD patients *
42.	Number of ADDITIONAL non-PD participants whose DNA will be available by the end of 2022 Can Include participants with blood/specimen but whose DNA has not been extracted yet
43.	Number of ADDITIONAL non-PD participants whose genotype will be available by the end of 2022
44.	Shipping ADDITIONAL DNA samples Mark only one oval.
	We anticipate we will be able to send samples to NIH for genotyping We anticipate we will not be able to send samples to NIH for genotyping We do not know the situation with transferring samples at this time Other:
Etl	hics Approval for Use of Data & Samples
45.	Institutional Review/Ethics Review Board Which ethics committee reviewed and approved this human subjects research?
46.	Date of ethics board approval
	Example: 7 January 2019



What are the terms of data sharing outlined in the consent documents? Mark only one oval. Use limited to study for which they were originally collected Use limited to Pl/Institution at which study was conducted Use limited to Parkinson's Disease reseach Consent silent on future use Consent explicitly allows sharing of data Other: 48. Sample Sharing * What are the terms of sample sharing outlined in the consent documents? Mark only one oval. Use limited to study for which they were originally collected Use limited to Pl/Institution at which study was conducted Use limited to Parkinson's Disease reseach Consent silent on future use Consent explicitly allows sharing of samples Other: 49. International Sharing * Does the consent allow sharing of data and/or samples outside of the country in which the study wa performed? Mark only one oval. No Consent silent on international sharing/storage Yes Other:	47.	Data Sharing *
Use limited to study for which they were originally collected Use limited to PI/Institution at which study was conducted Use limited to Parkinson's Disease reseach Consent silent on future use Consent explicitly allows sharing of data Other: 48. Sample Sharing * What are the terms of sample sharing outlined in the consent documents? Mark only one oval. Use limited to study for which they were originally collected Use limited to PI/Institution at which study was conducted Use limited to Parkinson's Disease reseach Consent silent on future use Consent explicitly allows sharing of samples Other: 49. International Sharing * Does the consent allow sharing of data and/or samples outside of the country in which the study was performed? Mark only one oval. No Consent silent on international sharing/storage Yes		What are the terms of data sharing outlined in the consent documents?
Use limited to PI/Institution at which study was conducted Use limited to Parkinson's Disease reseach Consent silent on future use Consent explicitly allows sharing of data Other: 48. Sample Sharing * What are the terms of sample sharing outlined in the consent documents? Mark only one oval. Use limited to study for which they were originally collected Use limited to PI/Institution at which study was conducted Use limited to Parkinson's Disease reseach Consent silent on future use Consent explicitly allows sharing of samples Other: 49. International Sharing * Does the consent allow sharing of data and/or samples outside of the country in which the study was performed? Mark only one oval. No Consent silent on international sharing/storage Yes		Mark only one oval.
Use limited to Parkinson's Disease reseach Consent silent on future use Consent explicitly allows sharing of data Other: 48. Sample Sharing * What are the terms of sample sharing outlined in the consent documents? Mark only one oval. Use limited to study for which they were originally collected Use limited to PI/Institution at which study was conducted Use limited to Parkinson's Disease reseach Consent silent on future use Consent explicitly allows sharing of samples Other: 49. International Sharing * Does the consent allow sharing of data and/or samples outside of the country in which the study was performed? Mark only one oval. No Consent silent on international sharing/storage Yes		Use limited to study for which they were originally collected
Consent silent on future use Consent explicitly allows sharing of data Other: What are the terms of sample sharing outlined in the consent documents? Mark only one oval. Use limited to study for which they were originally collected Use limited to PI/Institution at which study was conducted Use limited to Parkinson's Disease reseach Consent silent on future use Consent explicitly allows sharing of samples Other: Use International Sharing * Does the consent allow sharing of data and/or samples outside of the country in which the study waperformed? Mark only one oval. No Consent silent on international sharing/storage Yes		Use limited to PI/Institution at which study was conducted
Consent explicitly allows sharing of data Other: 48. Sample Sharing * What are the terms of sample sharing outlined in the consent documents? Mark only one oval. Use limited to study for which they were originally collected Use limited to Pl/Institution at which study was conducted Use limited to Parkinson's Disease reseach Consent silent on future use Consent explicitly allows sharing of samples Other: 49. International Sharing * Does the consent allow sharing of data and/or samples outside of the country in which the study wa performed? Mark only one oval. No Consent silent on international sharing/storage Yes		Use limited to Parkinson's Disease reseach
Other: 48. Sample Sharing * What are the terms of sample sharing outlined in the consent documents? Mark only one oval. Use limited to study for which they were originally collected Use limited to Pl/Institution at which study was conducted Use limited to Parkinson's Disease reseach Consent silent on future use Consent explicitly allows sharing of samples Other: 49. International Sharing * Does the consent allow sharing of data and/or samples outside of the country in which the study was performed? Mark only one oval. No Consent silent on international sharing/storage Yes		Consent silent on future use
48. Sample Sharing * What are the terms of sample sharing outlined in the consent documents? Mark only one oval. Use limited to study for which they were originally collected Use limited to PI/Institution at which study was conducted Use limited to Parkinson's Disease reseach Consent silent on future use Consent explicitly allows sharing of samples Other: 49. International Sharing * Does the consent allow sharing of data and/or samples outside of the country in which the study was performed? Mark only one oval. No Consent silent on international sharing/storage Yes		Consent explicitly allows sharing of data
What are the terms of sample sharing outlined in the consent documents? Mark only one oval. Use limited to study for which they were originally collected Use limited to PI/Institution at which study was conducted Use limited to Parkinson's Disease reseach Consent silent on future use Consent explicitly allows sharing of samples Other: 19. International Sharing * Does the consent allow sharing of data and/or samples outside of the country in which the study was performed? Mark only one oval. No Consent silent on international sharing/storage Yes		Other:
What are the terms of sample sharing outlined in the consent documents? Mark only one oval. Use limited to study for which they were originally collected Use limited to PI/Institution at which study was conducted Use limited to Parkinson's Disease reseach Consent silent on future use Consent explicitly allows sharing of samples Other: 19. International Sharing * Does the consent allow sharing of data and/or samples outside of the country in which the study was performed? Mark only one oval. No Consent silent on international sharing/storage Yes		
What are the terms of sample sharing outlined in the consent documents? Mark only one oval. Use limited to study for which they were originally collected Use limited to PI/Institution at which study was conducted Use limited to Parkinson's Disease reseach Consent silent on future use Consent explicitly allows sharing of samples Other: 19. International Sharing * Does the consent allow sharing of data and/or samples outside of the country in which the study was performed? Mark only one oval. No Consent silent on international sharing/storage Yes	48	Sample Sharing *
Use limited to study for which they were originally collected Use limited to PI/Institution at which study was conducted Use limited to Parkinson's Disease reseach Consent silent on future use Consent explicitly allows sharing of samples Other: 19. International Sharing * Does the consent allow sharing of data and/or samples outside of the country in which the study was performed? Mark only one oval. No Consent silent on international sharing/storage Yes	10.	·
Use limited to PI/Institution at which study was conducted Use limited to Parkinson's Disease reseach Consent silent on future use Consent explicitly allows sharing of samples Other: Use limited to Parkinson's Disease reseach Consent silent on future use Consent explicitly allows sharing of samples Other: Mark only one oval. No Consent silent on international sharing/storage Yes		Mark only one oval.
Use limited to Parkinson's Disease reseach Consent silent on future use Consent explicitly allows sharing of samples Other: Use limited to Parkinson's Disease reseach Consent silent on future use Consent explicitly allows sharing of samples Other: Use limited to Parkinson's Disease reseach Samples Consent silent on future use Samples Other: Where International Sharing of samples outside of the country in which the study was performed? Mark only one oval. No Consent silent on international sharing/storage Yes		Use limited to study for which they were originally collected
Consent silent on future use Consent explicitly allows sharing of samples Other: 149. International Sharing * Does the consent allow sharing of data and/or samples outside of the country in which the study was performed? 15 Mark only one oval. 16 No 17 Consent silent on international sharing/storage 17 Yes		Use limited to PI/Institution at which study was conducted
Consent explicitly allows sharing of samples Other: Other: Does the consent allow sharing of data and/or samples outside of the country in which the study was performed? Mark only one oval. No Consent silent on international sharing/storage Yes		Use limited to Parkinson's Disease reseach
Other: 49. International Sharing * Does the consent allow sharing of data and/or samples outside of the country in which the study was performed? Mark only one oval. No Consent silent on international sharing/storage Yes		Consent silent on future use
49. International Sharing * Does the consent allow sharing of data and/or samples outside of the country in which the study was performed? Mark only one oval. No Consent silent on international sharing/storage Yes		Consent explicitly allows sharing of samples
Does the consent allow sharing of data and/or samples outside of the country in which the study was performed? Mark only one oval. No Consent silent on international sharing/storage Yes		Other:
Does the consent allow sharing of data and/or samples outside of the country in which the study was performed? Mark only one oval. No Consent silent on international sharing/storage Yes		
Does the consent allow sharing of data and/or samples outside of the country in which the study was performed? Mark only one oval. No Consent silent on international sharing/storage Yes		
Mark only one oval. No Consent silent on international sharing/storage Yes	49.	_
No Consent silent on international sharing/storage Yes		
Consent silent on international sharing/storage Yes		Mark only one oval.
Yes		◯ No
		Consent silent on international sharing/storage
Other:		Yes
		Other:



50.	Commercial Use *
	Does the consent allow for commercial use of the samples/data?
	Mark only one oval.
	No
	Consent silent on commercial use
	Yes
	Other:
	Other.
- 1	Data Stavens I acation *
51.	Data Storage Location * Does the consent form specify where data will be stored?
	Mark only one oval.
	Storage location specified in consent
	Consent silent on storage location
	Consent allows storage outside the institution and/or on cloud servers
	Other:
52.	Duration of Storage *
	Is the duration of data storage limited?
	Mark only one oval.
	Limited
	Consent silent on duration of storage
	Unlimited
	Other:
5 0	If storage duration is limited, when does it expire?
53.	ii storage daration is innited, when does it expire:
	Example: 7 January 2019

Collected Data



54.	Basic clinical variables available for most participants - multiple responses are possible
	possible
	Tick all that apply.
	Gender/sex
	Age at diagnosis
	Age at onset
	Censored vital status (Alive/Dead with Date)
	Family history of PD (Basic - present/absent)
	Family history (Detailed - structure, number of affected family members, c/w AD/AR/X-
	linked)
	Education level
	Self-reporting race
	Medical history (common/PD related diseases)
	Diagnostic certainty
	Time to major PD events (e.g., HY3, wearing-off, dyskinesia)
	Diagnosis checklist (MDS diagnostic criteria)
55.	Other samples available for some participants
	Tick all that apply.
	Plasma
	Serum
	RNA
	PBL (Peripheral blood lymphocytes)
	LCL (Lymphoblastoid cell lines)
	Skin biopsy
	iPS □
	Post-mortem brain
	CSF



56. *Omics Data Availability

Tick all that apply.

	Blood	Brain	Other Tissues
RNAseq			
Methylation			
Metabolomics			
Proteomics			
Exome/Genome sequence files			

17



57. Clinical Data Availability *

Mark only one oval per row.

	Cross-sectional	Longitudinal	None
Medication information			
Global PD severity (e.g. CISI-PD)			
Lifestyle (smoking, alcohol, income)			
Environment (residence, work)			
Head trauma history			
Hoehn and Yahr			
UPDRS (original/MDS)			
Cognitive measurements			
REM sleep behavior disorder			
Autonomic function			
Depression/anxiety measurement			
Sleep assessment			
Vitals (Height, weight, BMI, BP)			
Orthostatic hypotension			
Smell assessment			
Activities of daily living (e.g. Schwab & England)			
Quality of life (e.g. PDQ39/PDQ8)			
Pain assessment			
Blood CBC, Chem			



	Cross-sectional	Longitudinal	None		
MRI					
DATSCAN					
	availability * available for more th one oval.	an half (PD) partic	ipants?		
Yes No					
ree note	(describe any ac	lditional data t	ypes you	can provide)	
Free note	(describe any ac	Iditional data 1	ypes you	can provide)	
Free note	(describe any ac	Iditional data t	ypes you	can provide)	
				can provide) urther follow-up	/research
Are you ak	ole to recontact p				/research
Are you abstudies?	ole to recontact p				/research



62.	The GP2 monogenic hub will collate possible monogenic cases. If you are interested, please indicate here and you will be recontacted by the Monogenic team
	Mark only one oval.
	Yes No
63.	In publication for research using GP2 data, do you support: Transparency, Collaboration, and Open Science is GP2's policy goal. We would like to know your general position on this. Multiple responses possible
	Tick all that apply. Open data Open code (analytical scripts) Publishing with CC-BY license AND immediate free access through PubMed Central
64.	Would you like to request analytical support from the GP2 data analysis team?
	Tick all that apply. Yes Not sure No
65.	Please send the consent form, protocol and case report form to cohort@gp2.org And any comments here.



5. Map of contributing cohorts and genotyping tracker

Below is a map of the geographic distribution of cohorts and the progress of genotyping (as of 15th May 2022). The live map is regularly updated and can be viewed on the GP2 website at https://gp2.org/cohort-dashboard/.



6. Contributing Institutions

Details of institutions contributing PD cohorts to GP2 can be found on the GP2 webpage at https://gp2.org/members/



7. Sample preparation and shipment guidelines for genotyping at NIH, Maryland, USA

Requirements for shipment of samples to NIH for GP2 genotyping

The Global Parkinson's Genetics Program (GP2) aims to genotype over 150,000 samples. The array of choice is the Illumina Infinium Global Diversity Array (GDA). This array is built on a high-density (1.9M total variants) single nucleotide polymorphism (SNP) global backbone optimized for cross-population imputation coverage of the human genome. In addition, a ~80K custom content (NeuroBooster, GitHub link) is added including: 1) known causal variants for various neurodegenerative diseases 2) imputation boosters for underrepresented populations. information the **GDA** can be found on array here: https://www.illumina.com/products/by-type/microarray-kits/infinium-global-diversity.html

DNA requirements:

- Concentration: 50ng/uL or greater, preferably measured with a Qubit (diluted in molecular grade water)
- Quantity: 1ug or more
- Quality: 260/280 ratio of ~1.8
- Final DNA concentration should be verified with Nanodrop or Qubit
- DNA should be aliquoted in screw-top 1.5~2ml microcentrifuge tubes.
- Label tubes clearly with the local sample ID and the submitter (PI, Institution).
- DNA aliquots may be shipped in plates only with prior approval -or- if DNA plates are prepared by a biorepository (Please contact <u>Dena Hernandez</u>for this)
 - All wells are filled in th 96-well plate
 - Should not have any empty wells except for the last plate

DNA Sample Manifest:

- Use this <u>DNA Sample Manifest template</u>.
- You will be issued a GP2 study_code to identify your cohort. Please ask if you haven't received one.
- Your Sample Manifest will be reviewed and QC'd by CIWG.
- After you receive the QC'd manifest back you can arrange the shipment.



Shipping Instructions:

- The GP2 study_code should be included in the first line of the delivery address (see below).
- Seal the microcentrifuge tubes containing your DNA with parafilm.
- Place the sealed microcentrifuge tubes in a small solid box for additional insulation during shipment. (Example here).
- To prevent sample tubes from moving during shipment, fill any remaining space in the box with clean tissue paper and/or bubble wrap prior to sealing.
- Include a printed copy of the DNA Sample Manifest in the shipment box with the samples (the QC'd version that was returned to you).
- Samples should be shipped with sufficient dry ice.
- Stick the dry ice label (<u>here</u>) to your outer box, or customs may refuse/delay the shipment.
- Label your outer box with the words "EXEMPT HUMAN SPECIMEN". Letter height should be at least 8mm. (Non-infectious, non-hazardous human specimens).
- Ensure the outer box is clearly labelled with the sender and receiver addresses.
- Ship the samples with FedEx. Email hernand@nih.gov or cohort@gp2.org for the FedEx account number.
- · Ship on a Monday or Tuesday.

Following receipt of your sample manifest, a specific GP2 code will be issued. This code should be included on the first line of the shipping address as below.

Shipping address:

Dena G. Hernandez_(specific GP2 study code)
Laboratory of Neurogenetics
National Institute on Aging, National Institutes of Health
Building 35, Room 1A215, 35 Convent Drive
Bethesda, MD 20892, USA

2 001 301 312 5871



8. Sample preparation and shipment guidelines for genotyping at Fulgent, California, USA.

Requirements for shipment of samples to Fulgent for GP2 genotyping

The Global Parkinson's Genetics Program (GP2) aims to genotype over 150,000 samples. The array of choice is the Illumina Infinium Global Diversity Array (GDA). This array is built on a high-density (1.9M total variants) single nucleotide polymorphism (SNP) global backbone optimized for cross-population imputation coverage of the human genome. In addition, a ~80K custom content (NeuroBooster, GitHub link) is added including: 1) known causal variants for various neurodegenerative diseases 2) imputation boosters for underrepresented populations. More information on the GDA array can be found here: https://www.illumina.com/products/by-type/microarray-kits/infinium-global-diversity.html

DNA requirements:

- Concentration: 50ng/uL or greater, preferably measured with a Qubit (diluted in molecular grade water)
- Quantity: 1ug or more
- Quality: 260/280 ratio of ~1.8
- · Final DNA concentration should be verified with Nanodrop or Qubit
- DNA aliquots may be shipped in plates if the plates are well sealed.
 - Assign each plate a unique ID or barcode, and ensure the sample positions specified in your sample manifest are correct.
- DNA aliquots can alternatively be shipped in 1.5 or 2ml screw-top tubes.
 - Label tubes clearly with the local sample ID and the submitter (PI, Institution).

IMPORTANT: Fulgent process the samples in batches of 48, and will charge GP2 for 48 samples even if a batch contains <48 samples. Therefore, please only send samples to Fulgent in multiples of 48. If you are planning to send more samples in the future, you can include any additional samples in your next shipment. If you have finished collecting samples and don't have enough to make up the last batch of 48, please email cohort@gp2.org and let us know how many additional samples you have.

1. DNA Sample Manifest:

- In advance of shipment, please complete the <u>DNA Sample Manifest template</u> (dictionary on second sheet).
- You will be issued a GP2 study_code to identify your cohort. Please ask if you haven't received one (first column in the manifest template).
- Email the completed manifest to Manuela Tan (<u>manuela.tan@ucl.ac.uk</u>) and cohort@gp2.org
- Your sample manifest will be reviewed and QC'ed by the Cohort Integration Working Group (CIWG).
- You will receive your finalised sample manifest back, as well as a second Fulgent Sample Manifest that you will need to print and include in the box with your samples.
 After you have received these manifests from the CIWG, you can arrange shipment of your samples.



2. Sample shipment:

- If you have aliquoted your DNA in plates, ensure the plates are well sealed and each plate has a unique ID.
- If you have aliquoted your DNA in 1.5 or 2mL microcentrifuge tubes, seal the tubes with parafilm. Place the sealed tubes in a small solid box for additional protection during shipment. (Example here). To prevent sample tubes from moving during shipment, fill any remaining space in the box with clean tissue paper and/or bubble wrap prior to sealing.
- Include a printed copy of the Fulgent Sample Manifest in the shipment box with your samples (the second manifest that was sent to you when your QC'ed sample manifest was returned).
- Ship the DNA samples with cold-packs (dry-ice is not necessary).
- Label your outer box with the words "EXEMPT HUMAN SPECIMEN". Letter height should be at least 8mm. (Non-infectious, non-hazardous human specimens).
- Ensure the outer box is clearly labelled with the sender and delivery addresses.
- The GP2 study_code should be included in the first line of the delivery address (see below).
- Ship the samples with FedEx. Email cohort@gp2.org for the FedEx account number.
- Ship on a Monday or Tuesday.
- When your shipment is arranged, email SeqService@fulgentgenetics.com and rblake@fulgentgenetics.com (Rachel Blake) to notify them that you are sending a shipment of samples for genotyping as part of the GP2 initiative. Include your tracking number and a copy of the Fulgent Sample Manifest with your email.

Shipping address:

Rachel Blake (GP2 study: "study_code")
Fulgent Genetics
4978 Santa Anita Avenue, Suite 205
Temple City, California 91780
United States of America

rblake@fulgentgenetics.com

Office: 626.350.0537 Fax: 626.454.1667 Cell: 626.238.4677



9. Sample preparation and shipment guidelines for genotyping at DZNE, Tübingen, Germany.

Instructions for shipment of samples to DZNE for GP2 genotyping

The Global Parkinson's Genetics Program (GP2) aims to genotype over 150,000 samples. The array of choice is the Illumina Infinium Global Diversity Array (GDA). This array is built on a high-density (1.9M total variants) single nucleotide polymorphism (SNP) global backbone optimized for cross-population imputation coverage of the human genome. In addition, a ~80K custom content (NeuroBooster, GitHub link) is added including: 1) known causal variants for various neurodegenerative diseases 2) imputation boosters for underrepresented populations. More information on the GDA array can be found here: https://www.illumina.com/products/by-type/microarray-kits/infinium-global-diversity.html

DNA requirements:

- Concentration: 50ng/ul-100ng/ul preferably measured with a Qubit
- · Quantity: 1ug or more
- Quality: 260/280 ratio of ~1.8
- · Final DNA concentration should be verified with Nanodrop or Qubit
- DNA for all the samples if feasible or for a subset should be visualised on gel: some degradation is tolerated, but extensively degraded material may not perform well in the assay.
- Samples should be resuspended in water, or 10 mM Tris 8.0, Qiagen EB (10 mM Tris 8.5), or low TE
- DNA aliquots may be shipped in plates if the plates are well sealed.
 - o All wells are filled in the 96-well plate
 - Should not have any empty wells except for the last plate
 - Please assign to each plate a unique ID or barcode
- DNA aliquots can alternatively be shipped in 1,5 or 2ml screw-top tubes with sample's ID clearly indicated.

DNA Sample Manifest:

- In advance of shipment, please email the electronic DNA Sample manifest to manuela.tan@ucl.ac.uk and cohort@gp2.org
- Use this <u>DNA Sample Manifest template</u>.
- Your Sample Manifest will be reviewed and QC'd by the cohort integration working group (CIWG).
- You will be issued a GP2 study_code to identify your cohort. Please ask if you haven't received one.
- After you receive the QC'd manifest back you can arrange the shipment



Shipping Instructions:

- The GP2 study_code should be included in the first line of the delivery address (see below).
- Ship the samples with FedEx. Email <u>patrizia.rizzu@dzne.de</u> for the FedEX account number before shipping.
- If you have aliquoted your DNA in plates, ensure the plates are well sealed and each plate has a unique ID.
- If you have aliquoted your DNA in microcentrifuge tubes, seal the tubes with parafilm.
 Place the sealed microcentrifuge tubes in a small solid box for additional insulation
 during shipment. (Example here). To prevent sample tubes from moving during
 shipment, fill any remaining space in the box with clean tissue paper and/or bubble
 wrap prior to sealing.
- Include a printed copy of the DNA Sample Manifest in the shipment box with the samples (the QC'd version that was returned to you).
- Samples should be shipped with sufficient dry ice. Stick the dry ice label (<u>here</u>) to your outer box, or customs may refuse/delay the shipment.
- Label your outer box with the words "EXEMPT HUMAN SPECIMEN". Letter height should be at least 8mm. (Non-infectious, non-hazardous human specimens).
- Ensure the outer box is clearly labelled with the sender and receiver addresses.
- Ship on a Monday or Tuesday.
- Email Patrizia Rizzu <u>patrizia.rizzu@dzne.de</u> a copy of the finalised sample manifest, and include the tracking number and expected delivery time once the shipment is arranged.

Following receipt of your sample manifest, a specific GP2 code will be issued. This code should be included on the first line of the shipping address as below.

Shipping address:

Patrizia Rizzu (specific GP2 code)
DZNE
Applied Genomics for Neurodegenerative Diseases
Otfried Muellerstrasse 23, 7th floor
Tuebingen 72076
Germany
Tel 004970719254082